News: Isis Pharmaceuticals Inc (ISIS.OQ)
28.88USD
11:18am EDT
$-0.41 (-1.40%)
$29.29
$29.08
$29.18
$28.73
69,515
507,698
$34.30
$7.55
Tue, Jul 30 2013
Isis eyes nationwide mobile payments launch this year
NEW YORK - Isis, a venture of three of the top U.S. mobile providers, said on Tuesday it would expand its much-delayed mobile payments service nationwide later in 2013 after it tested the concept with consumers in two markets.
Isis Pharma drug reduces blood fat by 64 pct in mid-stage study
- Isis Pharmaceuticals Inc said its experimental drug reduced the level of triglycerides, a type of fat in the blood that increases the risk of heart diseases, by up to 64 percent in a mid-stage trial.
Isis Pharma drug reduces blood fat by 64 pct in mid-stage study
July 22 - Isis Pharmaceuticals Inc said its experimental drug reduced the level of triglycerides, a type of fat in the blood that increases the risk of heart diseases, by up to 64 percent in a mid-stage trial.
Isis shares jump after experimental drug cuts blood fat
- Shares of Isis Pharmaceuticals Inc rose as much as 24 percent after the drugmaker said its experimental drug reduced triglycerides, a type of fat, in blood and increased the level of "good" cholesterol.
Roche to use Isis's technology to develop brain disorder drug
- Isis Pharmaceuticals Inc said it will form an alliance with Swiss drugmaker Roche Holding AG to develop treatments for Huntington's disease, a genetic brain disorder, based on the U.S. company's technology.
Roche to use Isis's technology to develop brain disorder drug
April 8 - Isis Pharmaceuticals Inc said it will form an alliance with Swiss drugmaker Roche Holding AG to develop treatments for Huntington's disease, a genetic brain disorder, based on the U.S. company's technology.
Press Releases
- Isis Pharmaceuticals To Review CHMP Opinion On KYNAMRO™
- Genzyme and Isis Provide Update on CHMP Opinion on KYNAMRO (mipomersen)
- Isis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
- Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
- Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
- Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
- Regulus to Host NASDAQ Closing Bell Ceremony on December 5, 2012
- Isis Pharmaceuticals To Provide Update On Its Metabolic Franchise
- Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
- Isis Pharmaceuticals To Present At The 24th Annual Piper Jaffray Healthcare Conference

